Register of Genetically Modified Organisms (GMOs)
Users in Ireland

The name and address of the notifier	Department of Tropical Medicine and International Health Royal College of Surgeons in Ireland 123 St Stephen's Green Dublin 2
The location (including, where necessary, the name of townland or townlands) of a deliberate release proposed under, or granted consent in accordance with, Part II of the GMO (Deliberate Release) Regulations 2003, S.I. No. 500 of 2003	Clinical Research Centre Beaumont Hospital Dublin 9
GMO Register No.	G0451-01
SNIF No.	B/IE/11/451(a) and B/IE/11/451(b)
The date or dates of a Deliberate Release	1st September 2011 to December 31st 2012
The description and intended uses of each GMO involved	A novel malaria vaccine comprising the following vectors: • Chimpanzee Adenovirus 63 CS (ChAd63 CS). This is a replication incompetent chimpanzee adenovirus which has been engineered to express the malaria circumsporozoite protein; • Modified Vaccinia virus Ankara CS (MVA CS). This is a replication incompetent virus related to the virus used in the successful smallpox vaccination campaign which has been engineered to express the malaria circumsporozoite protein. Clinical trial volunteers will be vaccinated with either ChAd63 CS alone or ChAd63 CS followed 8 weeks later by MVA CS.
The purpose of the deliberate release or placing on the market	The safety and immunogenicity of the novel malaria vaccine vectors
The date of receipt of a notification or amended notification	12th July 2011
The date of publication of a notice under article 15(1) or 29(3)	14th July 2011

The number of representations, if any, received under article 16(1)	0
The date of any request by the Agency for further information	30 August 2011
The date of receipt by the Agency of any further information	14 September 2011 – Requested information received. 31 January 2013 – Notifier advised the Agency that the clinical trial was completed at the end of December 2012. 24 June 2013 – Notifier submitted an end-of-study report to the Agency. Agency forwarded this report to the EU Commission on 3 July 2013. This Register entry is now considered "Inactive".
The date of receipt, or the date on which the Agency otherwise became aware, of any information or any other matter referred to in article 22(1)	
The date of any exercise by the Agency of its powers under article 22(1)	Approved by the Board 27 September 2011. Consent Conditions issued 29 September 2011
The date and nature of any decision by the Commission of the European Communities under Article 18 (1) or 23(2) of the Directive	
The date of withdrawal of a notification or an amended notification	